BRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months

Reuters

03 Apr

BRIEF-Akebia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months

April 3 (Reuters) - Akebia Therapeutics Inc AKBA.O:

AKEBIA THERAPEUTICS ANNOUNCES POSITIVE OPINION OF EUROPEAN MEDICINES AGENCY FOR XOANACYL®, AN ORAL THERAPY FOR CHRONIC KIDNEY DISEASE LICENSED TO AVEROA
AKEBIA THERAPEUTICS: EC WILL REVIEW CHMP RECOMMENDATION, FINAL DECISION EXPECTED IN ABOUT TWO MONTHS

Source text: ID:nGNX4P6T4q

Further company coverage: AKBA.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2524256115"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524256115\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524256115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524256115","market":"nz","top_or_hot":-1,"title":"BRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months</title></head><body><p><span>April 3 (Reuters)</span><span> - </span>Akebia Therapeutics Inc <span>AKBA.O</span>:</p><ul><li><p>AKEBIA THERAPEUTICS ANNOUNCES POSITIVE OPINION OF EUROPEAN MEDICINES AGENCY FOR XOANACYL®, AN ORAL THERAPY FOR CHRONIC KIDNEY DISEASE LICENSED TO AVEROA</p></li><li><p>AKEBIA THERAPEUTICS: EC WILL REVIEW CHMP RECOMMENDATION, FINAL DECISION EXPECTED IN ABOUT TWO MONTHS</p></li></ul><p>Source text: <span>ID:nGNX4P6T4q</span></p><p>Further company coverage: <span>AKBA.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-03 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months</title></head><body><p><span>April 3 (Reuters)</span><span> - </span>Akebia Therapeutics Inc <span>AKBA.O</span>:</p><ul><li><p>AKEBIA THERAPEUTICS ANNOUNCES POSITIVE OPINION OF EUROPEAN MEDICINES AGENCY FOR XOANACYL®, AN ORAL THERAPY FOR CHRONIC KIDNEY DISEASE LICENSED TO AVEROA</p></li><li><p>AKEBIA THERAPEUTICS: EC WILL REVIEW CHMP RECOMMENDATION, FINAL DECISION EXPECTED IN ABOUT TWO MONTHS</p></li></ul><p>Source text: <span>ID:nGNX4P6T4q</span></p><p>Further company coverage: <span>AKBA.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0DI:1","article_id":"2524256115","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524256115","pubTimestamp":1743682335,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two MonthsApril 3 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS ANNOUNCES POSITIVE OPINI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKBA":"Akebia Therapeutics, Inc."},"translate_title":"简介-Akebia Therapeutics EC将审查CHMP建议，预计在大约两个月内做出最终决定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":0.9},"content_text":"BRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two MonthsApril 3 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS ANNOUNCES POSITIVE OPINION OF EUROPEAN MEDICINES AGENCY FOR XOANACYL®, AN ORAL THERAPY FOR CHRONIC KIDNEY DISEASE LICENSED TO AVEROAAKEBIA THERAPEUTICS: EC WILL REVIEW CHMP RECOMMENDATION, FINAL DECISION EXPECTED IN ABOUT TWO MONTHSSource text: ID:nGNX4P6T4qFurther company coverage: AKBA.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}